



# DURECT Corporation Invites You to Join its Fourth Quarter and Year-End 2004 Conference Call on the Web

CUPERTINO, Calif., Jan. 20 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter and year-end 2004 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 10, 2005 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom Schreck, Chief Financial Officer and Felix Theeuwes, Chairman and Chief Scientific Officer.

(Photo: NewsCom: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO> )

What: DURECT Corporation's Fourth Quarter and Year-End 2004 Earnings Conference Call

When: Thursday, February 10th, 2005, 4:30 p.m. EST (1:30 p.m. PST)

Where: [www.durect.com](http://www.durect.com) and click 'Investor Relations'  
Live over the Internet — Simply log on to the Web at the address listed above.

If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceuticals systems company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein and small molecule delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the DURIN(TM) Biodegradable Implant (drug-loaded implant system) and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system). DURECT also collaborates with pharmaceutical companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which three are in collaboration with pharmaceutical partners. Additional information about DURECT is available at [www.durect.com](http://www.durect.com).

NOTE: SABER(TM), ORADUR(TM), DURIN(TM) and MICRODUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.



SOURCE DURECT Corporation  
01/20/2005

CONTACT:

Schond L. Greenway  
Executive Director, Investor Relations and  
Strategic Planning, of DURECT Corporation,  
408-777-1417

/Photo: NewsCom: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>

AP Archive: <http://photoarchive.ap.org>

PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840/

/Web site: <http://www.durect.com/>

01/20/2005 07:30 EST <http://www.prnewswire.com>